Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
AI, Machine Learning & Computational Drug Design | Q&As & Interviews

Interview with Martin Fergie, Lecturer in Health Sciences at the University of Manchester 

Edited by Tia Byer | 18 April 2023
Martin Fergie, Lecturer in Health Sciences at the University of Manchester, discusses the challenges and future opportunities of AI and ML for bioinformatics.
https://www.youtube.com/watch?v=mP7j4ECn_Co

Get your weekly dose of industry news and announcements here, and keep up to date with the latest ‘Industry Spotlight’ posts. 

Visit our Omics Portal to learn more about the latest research into spatial omics and its developments. If you’d like to register your interest for Oxford Global‘s upcoming Spatial Biology UK: In-Person event, click here.

Speaker Biographies

Martin Fergie is a machine learning and computer vision researcher at the University of Manchester in the Division of Informatics, Imaging and Data Sciences. His research interests are focused on using machine learning models to predict disease outcomes from medical imaging data. Key projects include: predicting breast cancer risk from screening mammograms; predicting clinical outcomes for cancer using multiplex immunofluorescence tissue imaging.

Martin is currently taking part in the InnovateUK ICURe programme to identify opportunities to help relieve the workload burden on pathologists by applying artificial intelligence in clinical digital pathology.

Related Resources

Novo Nordisk Foundation and NVIDIA to Launch a State-of-the-Art National AI Research Centre

Novo Nordisk and NVIDIA join forces to build an AI supercomputer which will be housed in Denmark's national centre for AI innovation.
Read More

AI-driven High Throughput Screening for Targeted Drug Discovery

Artificial Intelligence (AI) has significantly transformed high throughput screening (HTS) in drug discovery, increasing efficiency, accuracy, and predictive capabilities in early drug development stages. This research highlights AI's integration into HTS processes, showcasing improved outcomes in hit identification, assay optimization, and target validation, thus accelerating and refining the search for new medications.
Read More

Related Online Activities

Join the conversation with our upcoming Monthly Science Exchanges and Webinars:
20/03/24
The Design of Novel Drugs with Generative AI
28/03/24
Generative AI and Large Language Models for Quantitative and Systems Pharmacology